Spots Global Cancer Trial Database for Circulating Tumor Cells in Prostate Cancer Patients
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Circulating Tumor Cells in Prostate Cancer Patients
Official Title: Circulating Tumor Cells in Patients Undergoing Stereotactic Body Radiotherapy for Low- and Intermediate-Risk Prostate Cancer
Study ID: NCT01414712
Conditions
Interventions
Study Description
Brief Summary: The purpose of this study is to determine if a non-invasive cancer treatment, high-dose stereotactic body radiotherapy (SBRT), is associated with changes in circulating tumor cells counts in patients with low- and intermediate-risk prostate cancer.
Detailed Description: SBRT (stereotactic body radiotherapy) may decrease or actually increase CTC levels in patients with cancer, and knowledge about the effects of different therapies, including SBRT, on CTC levels will be of general interest to the oncology community. Patients will undergo blood draws at defined times as indicated below. 1. Prior to CT-simulation, but more than 2 days after digital rectal examination 2. Within 24 hours following CT simulation (an endorectal balloon is used at the time of simulation) 3. Within 24 hours following the first treatment 4. Within 24 hours following the third treatment 5. Within 1 week following the fifth treatment
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
Locations
University of Texas Southwestern Medical Center, Dallas, Texas, United States
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
